Regulators are locking in new 2026 stars for plans if they’re higher under the new methodology. But the recalculation basically results in no change to average star ratings unless you’re Clover, analysts say.
The Kansas High Value Network's seven members together command $545 million in net revenue, and hope to improve quality and efficiency through shared services and value-based contracting.
The company is working to build a natively integrated enterprise resource planning (ERP) suite exclusively for healthcare operations that will collect financial, operational and clinical data in one unified system.
The HHS secretary announced over $700 million spread across various Substance Abuse and Mental Health Services Administration (SAMHSA) initiatives, including a new effort called the Safety Through Recovery, Engagement, and Evidence-based Treatment and Support (STREETS) Program.
A first-of-its-kind flu shot is one step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for approval. The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older. Moderna is...
The Ebola outbreak in Congo that’s spread across parts of Africa has killed more than 200 people in its first month and is considered the worst known outbreak at this stage, the Africa Centres for Disease Control and Prevention (Africa CDC) said Thursday. Ebola cases have surged 38 percent since last week, spreading across 32...
Kardigan was able to upsize its IPO, raising more cash for three drug candidates in mid-stage clinical development for cardiovascular conditions with no available therapies. All three programs are expected to report key data in 2027 that could pave the way for Phase 3 testing. The post Kardigan’s IPO Lands $400M for Drugs That Get to Root Causes of Heart Diseases appeared first on MedCity News .
A recent JAMA editorial from two radiologists argues that elective whole-body MRI scan companies are misleading consumers about the benefits of said scans. The radiologists argue the MRIs are more likely to trigger harmful downstream procedures than they are to save lives. Not surprisingly, the three most prominent companies offering these scans denied the charge. The post Researchers Say Whole-Body MRI Companies Are Inflating the Scans’ Medical Benefits appeared first on MedCity News .
Making good on its threat, Eli Lilly has begun eliminating mandated price breaks to a few dozen hospitals that participate in a federal drug discount program.